Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cimdelirsen, a novel ligand-conjugated, hepatic-targeted antisense oligonucleotide under investigation, aims to diminish growth hormone receptor (GHr) synthesis. This inhibits the harmful effects of growth hormone (GH) hypersecretion and lowers circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Cimdelirsen, a novel ligand-conjugated, hepatic-targeted antisense oligonucleotide under investigation, aims to diminish growth hormone receptor (GHr) synthesis. This inhibits the harmful effects of growth hormone (GH) hypersecretion and lowers circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients. |
Molecular Weight | N/A |
CAS No. | 2131025-82-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cimdelirsen 2131025-82-4 inhibitor inhibit